UroGen Pharma/$URGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
- Ticker
- $URGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 300
- Headquarters
- Princeton, United States
- Website
- www.urogen.com
UroGen Pharma Metrics
BasicAdvanced
$1.6B
-
-$1.97
1.58
-
Price and volume
Market cap
$1.6B
Beta
1.58
52-week high
$50.81
52-week low
$16.50
Average daily volume
1M
Financial strength
Current ratio
3.802
Quick ratio
3.177
Long term debt to equity
-1.466
Total debt to equity
-1.481
Interest coverage (TTM)
-4.11%
Profitability
EBITDA (TTM)
-66.345
Gross margin (TTM)
90.85%
Net profit margin (TTM)
-51.73%
Operating margin (TTM)
-35.32%
Effective tax rate (TTM)
0.48%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
-18.06%
Return on equity (TTM)
86.49%
Valuation
Price to revenue (TTM)
8.576
Price to book
-12.06
Price to tangible book (TTM)
-12.06
Price to free cash flow (TTM)
-10.171
Free cash flow yield (TTM)
-9.83%
Free cash flow per share (TTM)
-3.217
Growth
Revenue change (TTM)
100.27%
Earnings per share change (TTM)
-39.79%
3-year revenue growth (CAGR)
37.55%
3-year earnings per share growth (CAGR)
-25.16%
What the Analysts think about UroGen Pharma
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
Analyst projections of the future price of UroGen Pharma stock.
Bulls say / Bears say
ZUSDURI is scaling quickly: it generated $50.4 million in second-quarter revenue, up 73% on the previous quarter, while repeat prescribers rose to 45% of its prescriber base. That combination points to growing adoption and repeat use. (GlobeNewswire)
ZUSDURI’s trial data suggest its treatment effect can last: 64.5% of patients who achieved a complete response were estimated to remain in response at 36 months, and median response duration had not been reached. The reported durability did not require maintenance therapy. (GlobeNewswire)
UGN-103 could extend UroGen’s bladder-cancer franchise with a follow-on product: its Phase 3 trial reported 94.5% six-month duration of response, and the formulation is intended to simplify manufacturing and preparation. If approved, it could build on ZUSDURI’s commercial base. (GlobeNewswire, GlobeNewswire)
Funding remains a risk while UroGen invests for growth: it had $108 million in cash and marketable securities at quarter-end and raised its 2026 operating-expense outlook to $260–270 million. The company says it may need more capital if product sales do not generate enough cash. (GlobeNewswire, Last10K)
JELMYTO appears to be a slower-growing product: UroGen forecasts 2026 revenue growth of just 3–7%. Teva may also sell a generic from September 2030 if it receives FDA approval. (GlobeNewswire, Last10K)
The pipeline is not yet a dependable revenue hedge: UGN-103 still needs FDA approval, and the company warns that UTOPIA’s data may not be sufficient to support it. UGN-501 is only at the start of clinical development. (Last10K, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
UroGen Pharma Financial Performance
Revenues and expenses
UroGen Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
UroGen Pharma News
AllArticlesVideos
Funds containing UroGen Pharma
Fund name | Fund size | $URGN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.15% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.15% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.15% |
iShares Ageing Population$AGED | $953M | 0.14% |
iShares Ageing Population£AGES | $953M | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.